Schonfeld Strategic Advisors LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.

Quarter-by-quarter ownership
Schonfeld Strategic Advisors LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2022$635,836
+32.2%
14,266
+1.2%
0.01%
+25.0%
Q1 2022$481,000
-8.7%
14,100
+3.3%
0.00%
-20.0%
Q4 2021$527,000
-82.8%
13,643
-76.0%
0.01%
-84.4%
Q3 2021$3,068,000
+19.3%
56,807
-26.1%
0.03%
+18.5%
Q2 2021$2,571,000
+261.1%
76,880
+122.4%
0.03%
+200.0%
Q1 2021$712,00034,5700.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2021
NameSharesValueWeighting ↓
Kynam Capital Management, LP 2,600,000$88,218,00012.13%
Octagon Capital Advisors LP 759,898$25,783,3393.59%
TSP Capital Management Group, LLC 251,895$8,546,8003.08%
ACUTA CAPITAL PARTNERS, LLC 122,343$4,151,0982.81%
5AM Venture Management, LLC 310,270$10,527,4612.62%
COMMODORE CAPITAL LP 631,665$21,432,3932.41%
RTW INVESTMENTS, LP 3,463,201$117,506,4102.24%
Eversept Partners, LP 785,740$26,660,1582.23%
Redmile Group, LLC 1,696,004$57,545,4162.21%
Affinity Asset Advisors, LLC 87,031$2,952,9621.03%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders